Skip to main content
    I

    Inhibrx Biosciences, Inc. (INBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $90.50
    +5.24 (+6.15%)

    Market Cap: $1.25B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(5/10)
    Avg Surprise
    +812.98%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.35
    Range$-2.57 - $-2.14
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.39+1.5%
    60d ago$-2.39+1.5%
    30d ago$-2.39+1.5%
    7d ago$-2.350.0%
    Current$-2.35
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-3.42
    Range$-3.75 - $-3.10
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.42---
    Sep 26EST
    		-$-2.35---
    Jun 26
    Reported Aug 13
    		$-2.34$-2.50+6.40%Beat-26.5%
    Mar 26
    Reported May 14
    		$-2.15$-1.20-79.17%Miss+23.2%
    Dec 25
    Reported Mar 19
    		$-2.11$-1.63-29.45%Miss+31.7%
    Sep 25
    Reported Nov 14
    		$-2.28$-1.72-32.56%Miss+19.7%
    Jun 25
    Reported Aug 13
    		$-1.85$-2.60+28.85%Beat-101.5%
    Mar 25
    Reported May 14
    		$-2.80$-3.12+10.26%Beat-94.4%
    Dec 24
    Reported Mar 17
    		$-3.09$-1.44-114.58%Miss-
    Sep 24
    Reported Nov 14
    		$-2.84$-3.70+23.24%Beat-
    Jun 24
    Reported Aug 13
    		$125.48$-1.52+8355.26%Beat-
    Mar 24
    Reported Jun 3
    		$-1.44$-1.04-38.46%Miss-

    Key Metrics

    Valuation
    P/E Ratio-10.19EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1774.00%ROIC-103.79%
    Financial Health
    Debt/Equity-3.33xInterest Coverage125.28x
    Current Ratio5.07xQuick Ratio5.07x
    Trading Statistics
    Beta3.82Avg Volume250.83K
    52-Week High$155.2952-Week Low$28.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$91.95
    SMA 20$97.82
    SMA 50$103.63
    SMA 200$91.48
    EMA 10$92.12
    EMA 20$96.33
    EMA 50$99.74
    EMA 200$88.89

    MACD

    Line: -4.76Signal: -3.73Hist: -1.03

    ADX

    ADX: 21.1+DI: 19.9-DI: 31.1

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$103.70

    Bollinger Bands

    Upper Band$112.69
    Lower Band$82.95
    %B Position3040%(Upper)
    Band Width0.25

    RSI (14-Day)

    Neutral
    39.5

    Momentum Oscillators

    Stoch %K13.7
    Stoch %D9.2
    Williams %R-71.6
    ROC (10d)-7.6%
    Momentum-7.43
    CCI (20d)-95.2
    MFI (14d)24.8

    Volatility Measures

    ATR (14d)$5.97(6.6%)
    StdDev (20d)7.43
    Hist Vol56.3%(High)

    Volume Flow

    VWAP$89.79
    OBV14.4M
    AD Line4.6M
    CMF (20d)-0.268

    Volume Metrics

    Avg Vol (20d)246.9K
    Vol Ratio0.9x
    VWMA (20d)$98.84

    Pivot Points

    R3$90.95
    R2$89.15
    R1$87.21
    Pivot Point$85.41
    S1$83.46
    S2$81.66
    S3$79.72

    Advanced Oscillators

    TSI-24.91
    Ultimate Osc42.1
    KST-137.85

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$1.30M$0$100,000$0$100,000$0$1.63M$119,000
    Cost of Revenue$0$0$564,000$0$0$0$689,000$0$0$0$298,000$0
    Gross Profit$0$0$-564,000$0$1.30M$0$100,000$0$100,000$0$1.34M$119,000
    Operating Expenses$32.15M$30.93M$30.92M$33.81M$28.69M$42.90M$50.03M$46.80M$161.00M$73.83M$89.63M$45.95M
    R&D$23.90M$25.22M$25.35M$28.54M$22.27M$36.88M$33.37M$38.89M$67.63M$63.85M$81.84M$38.06M
    SG&A$8.25M$5.71M$5.57M$5.28M$6.42M$6.02M$16.66M$7.90M$93.37M$9.97M$7.83M$7.89M
    Operating Income$-32,149,000$-30,927,000$-30,923,000$-33,812,000$-27,389,000$-42,901,000$-49,928,000$-46,797,000$-160,898,000$-73,825,000$-88,289,000$-45,827,000
    Interest Income$1.26M$1.01M$1.31M$1.78M$2.12M$2.33M$2.00M$2.89M$2.74M$3.30M$0$2.32M
    Interest Expense$5.69M$3.51M$3.19M$3.18M$3.14M$2.69M$0$0$5.36M$8.13M$8.22M$8.15M
    Income Before Tax$-36,647,000$-33,441,000$-32,834,000$-35,256,000$-28,652,000$-43,311,000$-47,865,000$-43,864,000$1.86B$-78,710,000$-93,608,000$-51,787,000
    Income Tax Expense$3,000$0$0$0$2,000$0$0$0$2,000$0$-4,000$2,000
    Net Income$-36,650,000$-33,441,000$-32,834,000$-35,256,000$-28,654,000$-43,311,000$-47,865,000$-43,864,000$1.86B$-78,710,000$-93,604,000$-51,789,000
    EBITDA$-30,403,000$-29,670,000$-29,756,000$-32,637,000$-26,348,000$-41,743,000$-49,179,000$-45,996,000$1.86B$-72,282,000$-87,991,000$-44,419,000
    EBIT$-32,217,000$-30,939,000$-30,962,000$-33,858,000$-27,635,000$-42,951,000$-49,868,000$-46,756,000$1.86B$-73,884,000$-88,289,000$-45,962,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INBX

    News

    CEO Mark Lappe buys 10,040 shares in Inhibrx Biosciences stock

    Inhibrx Biosciences CEO Mark Lappe purchased 10,040 shares of the company's stock on October 14, 2026, through two family trusts. This insider buying follows a significant 145% return for the stock over the past year...

    ad-hoc-news.de•10/15/26•Bullish

    Form 4 Inhibrx Biosciences Inc: Mark Lappe (Director, CEO) For: 14 October

    This article reports a Form 4 filing for Inhibrx Biosciences Inc, detailing a transaction by Mark Lappe, who serves as both Director and CEO. The filing pertains to an event on October 14. The piece briefly mentions...

    Investing.com India•10/14/26•Neutral

    Inhibrx CEO Mark Lappe buys over $848k in company stock

    Inhibrx CEO Mark Lappe recently purchased over $848,000 worth of company stock through various trusts, acquiring 10,040 shares at prices ranging from $84.0707 to $85.76 per share. This comes as the stock shows a 145%...

    Investing.com•10/14/26•Somewhat-Bullish

    Form 4 Inhibrx Biosciences Inc: Mark Lappe (Director, CEO) For: 14 October

    This article reports a Form 4 filing for Inhibrx Biosciences Inc, indicating that Mark Lappe, who serves as a Director and CEO...

    Investing.com UK•10/14/26•Neutral

    Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported.

    The CEO of Inhibrx Biosciences, Mark Lappe, reported that two family trusts, the Lappe Family Trust and the Lappe Descendants’ Trust, purchased a combined 10,040 shares of common stock on October 14...

    Stock Titan•10/14/26•Bullish

    INBX Valuation and Fair Value

    P/E
    -10.2x
    P/B
    -26.8x
    See GNG's fair value

    INBX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -103.8%
    ROE
    -1774.0%

    INBX Competitors

    CompanyTicker
    Nektar TherapeuticsNKTR
    Syndax Pharmaceuticals IncSNDX
    U.S. Physical Therapy, Inc.USPH
    InnovAge Holding CorpINNV
    Tyra Biosciences IncTYRA
    Tourmaline Bio Inc.TRML
    Alpha Tau Medical LtdDRTS
    Oric Pharmaceuticals IncORIC

    Sector: Healthcare

    INBX Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    INBX Bull Case vs Bear Case

    Bear case

    • INBX's quarterly revenue changed -100.0% year over year.

    INBX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -23.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.35
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About INBX

    Does INBX pay dividends?

    Inhibrx Biosciences, Inc. (INBX) does not currently pay a regular dividend.

    What is INBX's market cap?

    Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.25B with a current stock price of $90.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In